Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | GRK5 | P34947 | 1/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725776 | 0.68 | RET (1.00) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL6992906 | 0.66 | RET (0.59) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL6996064 | 0.62 | RET (0.49) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL27176638 | 0.60 | RET (0.56) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL3160122 | 0.60 | RET (0.47) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL23191244 | 0.58 | RET (0.46) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL4149675 | 0.58 | RET (0.46) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL2471569 | 0.58 | TSHR (0.57) | RETGRK5TYRO3DYRK1BCES1 | |
| SCHEMBL11093427 | 0.58 | RET (0.45) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL7381362 | 0.57 | RET (0.62) | RETGRK5TYRO3DYRK1BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187438-B2 | Derivatives of benzothiazines, preparation thereof and application thereof as drugs | PIERRE FABRE MEDICAMENT (FR) | 2015-11-17 | — | — | US | disclosed |
| EP-2403840-B1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PF MEDICAMENT (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | HSD11B1, CYP11B1, HSD17B11 | RET 2831/4885GRK5 651/4885TYRO3 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.